Pantoprazole

20 mg: Mild GERD & associated symptoms eg, heartburn, acid regurgitation, pain on swallowing. Long-term management & prevention of reflux oesophagitis relapse. Prevention of nonselective NSAID-induced gastroduodenal ulcers in patients at risk w/ need for continuous NSAID treatment. 40 mg: H pylori eradication in patients w/ peptic ulcers. 40 mg, inj: Duodenal & gastric ulcer. Moderate & severe reflux esophagitis. Zollinger-Ellison syndrome & other pathological hypersecretory conditions.

Tab Adult & adolescent ≥12 yr Mild reflux disease & associated symptoms 20 mg daily for 2-4 wk. Long-term management & prevention of reflux oesophagitis relapse 20 mg daily, may be increased to 40 mg daily. Reduce to 20 mg daily once relapse is controlled. Moderate & severe reflux oesophagitis 40 mg daily, may be increased to 2-tab 40 mg daily. Duration of treatment: 4-8 wk. Adult Duodenal & gastric ulcer 40 mg daily, may be increased to 2-tab 40 mg daily. Duration of treatment: Duodenal ulcer 2 wk. Gastric ulcer 4-8 wk. Prevention of NSAID-induced gastroduodenal ulcers in patient at risk 20 mg daily. H pylori eradication in gastric or duodenal ulcers 40 mg bd + amoxicillin 1,000 mg bd + clarithromycin 500 mg bd or 40 mg bd + metronidazole 500 mg bd + clarithromycin 500 mg bd or 40 mg bd + amoxicillin 1,000 mg bd + metronidazole 500 mg bd. Duration of treatment: 1-2 wk. Zollinger-Ellison syndrome & other pathological hypersecretory conditions Initially 80 mg daily, may be titrated up or down as needed. Inj Gastric & duodenal ulcer, moderate & severe reflux esophagitis 40 mg IV daily if oral therapy is inappropriate. Zollinger-Ellison syndrome & other pathological hypersecretory conditions Initially 80 mg IV daily, titrate dose as needed.